Data presented at #AHA19 showcased our ongoing commitment to putting patients first. We are partnering with healthcare professionals with the aim to create meaningful change in how #heartfailure is managed for patients living with the disease and its comorbidities, such as #T2D.
“My mantra my whole life was – whatever the problem, there’s always a path forward.” For patients with #heartfailure, we are helping to provide patients the right support to better manage their disease and keep moving forward with ease. #AHA19
Once doctors have established whether a patient has SCLC or NSCLC, they can test to identify the molecular features of their #lungcancer, called #biomarkers. These are integral to understanding patients’ genetic makeup and matching them to appropriate therapies. #LCAM #LCSM
An estimated 40% of patients who have been hospitalised for #heartfailure have #T2D. Right now, at #AHA19 we are connecting with healthcare professionals and experts to advance clinical discussions in bringing more options to patients.
It’s a fact: up to 1 in 5 people who have experienced a heart attack may go on to have another within one year. More can be done to reduce this risk in patients across the globe, and at #AHA19, we present data with the aim to improve outcomes for patients.
Despite medical advances, #heartfailure remains as life-threatening as some of the most common cancers in men (prostate and bladder) and women (breast). #AHA19 is our opportunity to present our latest research findings to help tackle this condition.
From new technologies and novel platforms to patient perspectives and innovation ideas, scientists from across BioPharmaceuticals R&D gathered at the Global Science Symposium to discuss, learn and be inspired. Our scientists describe the symposium in just one word...
Today, we joined @CRUKresearch for the opening of the Functional Genomics Centre in #Cambridge. Through our collaboration, we aim to deepen understanding of cancer biology and accelerate development of treatments for patients with #cancer. Full video here:
We have signed an agreement with Omron Healthcare to help improve lives and contribute to a better society through translating science & technology to enhance the whole patient experience, from diagnosis to treatment and post-treatment.
We believe #machinelearning and #deeplearning can help us make a big change in how we design new medicines. But collaboration –internally and externally – is essential to realising the potential of data science and #AI. Watch more: